Member Info for flyingmachine

....it can't come soon enough. The GDR test has some specific advantages over current PCR based lab tests for Covid-19 - simplicity, consistency, integrity and speed. It will therefore stand up very well against the current competition.

Roll on tomorrow, I will be shocked if we don't see a RNS before the week-end.

Goldsmith, not sure why you have brought a comparison of Optigene test and AVCT over to the ODX board? But since you have..... I wasn't aware that AVCT had a test? Will they?....maybe, perhaps even probably, but it will be the best? It will depend heavily on the final sensitivity and selectivity, it is not a 100% guarantee like some folks are trying to make out over there but good luck to them.

I have mentioned in a previous posting that the GDR PCR test has several advantages over current PCR based tests in hospital. Taken from the GDR RNS....
"The combination delivers several key competitive advantages to the genedrive test
compared to the liquid, kit-based assays already on market. The Genedrive® 96 SARS-CoV2-test is a final format
test which only requires the addition of patient sample, with no other user preparation required. Integrated
controls within each test give confidence to the user that the input sample is of good quality, and the integrity of
each reaction mix is confirmed with another internal standard. The temperature-stable nature of lyophilisation
technology means that the test can be transported globally without the need for refrigeration, which will support
global product distribution."

So simpler to process - less room for error and variance, integrated quality check, and quicker - eliminates multiple steps in the end-to-end PCR process.

So all good from GDR perpspective for PCR lab testing.

The Optigene test mentioned today neesd to run on Optisense instruments and if successful in their trials, will find their place in non-hospital settings - care home, clinics etc. I do not see as a threat to PCR lab based testing in hospitals which are the 'gold standard'.

Richard, Lab based antibody tests will be useless for mass population testing. Once the design freeze is announced it must be pretty obvious to most folk here that there will be many more POC antibody tests sold and used in the UK and rest of the world than the Lab based tests. One will not replace the other, they are both relevant.

Here is the quote from the Roche testing document.....
"A total of 204 samples from 69 symptomatic patients with a PCR confirmed SARS-CoV-2 infection were tested with the Elecsys® Anti-SARS-CoV-2 assay".

Don't be too confident that it is the 'best' antibody test.!

Roche tested their antibody test on just 69 people with Covid for sensitivity! Not that impressive for a multi billion company, guess they were trying to rush a little bit and get their first. I think the Gov are a lot more cautions now after the China debacle.
And look at reaction from someone from the diagnostic world regarding the Roche reporting on the quality of their antibody tests.....
https://twitter.com/deeksj/status/1261626751375093760

Don't get sucked in too quickly with media hype!

Doggy, in answer to your question re: Sona Nanotech (not in competition with ODX as it is a LFT antigen test to check if you have the active virus (so not an antibody test) gave an update on their progress on 12th May, here....

https://sonanano.com/sona-nanotech-provides-covid-19-antigen-test-progress-update/

So in competition with Avacta and slightly ahead of them if I read this update correctly. Cytiva are being smart and spreading their bets with multiple Covid plays even if they are in competition with each other.

MrSpeculator and Pigger, indeed, there are competitors but there should be room for everyone whoever is first, second or third. Even our partner Cytiva is collaborating with a potential competitor who seem to be just a bit further down the path of clinical trials for a POC Lateral Flow Test for Covid-19...

https://www.cytivalifesciences.com/en/us/coronavirus-update

https://sonanano.com/sona-nanotech-provides-covid-19-antigen-test-progress-update/

Come the 28th May I do not believe the hot topic of conversation will be the placing shares. The hot topic of conversation will be distribution, sales, profit margin, manufacturing, growth and how the SP and Mcap will be driven by these. Don't forget Mcap today is around £55m only. We have other Covid players out there with a MCap increase of £230m with no product on the market. So there is significant potential for GDR once the CE Mark is obtained this week.

Punter, the CEO has stated he expects it to happen this week and it is the company that makes the product that completes the documentation to show that the product meets CE standards. These are then passed to the notifiable body for cross checking that CE standards have been met. GDR has experience of getting the CE mark on their products so I do not see this as a problem, just a process. So I do not see any 'if' in this at all.

...and consider the affect on SP and Mcap of GDR when the CE Mark arrives in the next couple of days. GDR are at only £53m Mcap. Compare this to a.n.other well known Covid play that have had their Mcap go up over £230m and they haven't even got a proven product to test if someone has the active virus yet. This illustrates the significant affect on the GDR SP and Mcap when the RNS arrives this week.

taff, agree that there are prospects coming up for NCYT but the Director buys must indicate that no price sensitive news is imminent, otherwise would be classed as insider dealing?

hants, no further information so far. Imperial College and partners will not be under obligation to put news out to the general public but I still would expect them to provide updates to the EIT over the next few weeks and months, either directly from IC or any of their partners. Also, I would look out for updates on sources like MedRxiv. Unfortunately, Prof Molly Stevens doesn't appear on Twitter.

hants, I noted in your comment "To my knowledge..." comment in your 11.50 post today. So just to make you aware....

https://www.imperial.ac.uk/news/197236/rapid-coronavirus-test-receives-major-funding/

Keep your eyes open......

The further new articles portion of my post seems to have been curtailed from my earlier post, so the rest of it is here...

Further news articles:
https://www.alloaadvertiser.com/news/18426571.alva-firm-joins-uk-rapid-test-consortium/
http://dateway.net/ceo-jonathan-allis-is-appointed-president-of-the-uk-rapid-testing-consortium-uk-rtc-for-covid-19-by-the-uk-department-of-health-and-social-affairs/
https://www.dailymail.co.uk/news/article-8257233/Government-orders-50million-game-changing-immunity-tests.html - quote from Jonathan Allis, chairman of RTC, “We are close to picking up 100% of all cases where people have antibodies. Now it is just a question of scaling up the manufacturing process.”

Appendix – everything you want to know about COVID-19 testing (lots of it, including antibody testing!) :
https://institute.global/tony-blair/path-mass-testing
https://www.cebm.net/covid-19/molecular-and-antibody-point-of-care-tests-to-support-the-screening-diagnosis-and-monitoring-of-covid-19/
https://www.fiercebiotech.com/medtech/fda-increases-oversight-requirements-for-covid-19-antibody-tests
https://www.nsmedicaldevices.com/analysis/uk-covid-19-antibody-testing/

Special Note – before going through these notes please understand right from the start that the Mologic POC ‘at home’ antibody test kits are unrelated to the POC ‘at home’ antibody test kits being designed by the Rapid Test Consortium (RTC). ODC is part of the RTC. The Mologic POC tests have only 96% specificity so are not ‘up to the standard’ required for the UK Gov for mass population testing.
ODX is involved on two fronts with Anti-body testing for COVID-19 (to test if someone has had the virus), Lab based antibody testing (see part 1) and POC antibody testing (see part 2) :
1. Elisa Lab based anti-body testing :
https://mologic.co.uk/covid-19-update-17-april-2020/ - Mologic Update on 17th April- ELISA lab test at least 99% sensitivity, 98% specificity. Independently validated, submitted to PHE for approval. Meets minimum MHRA specification (see MHRA link below). Ignore POC test in this Mologic update, it is for Mologic POC test and not the RTC POC test.
https://mologic.co.uk/mologic-launches-new-lab-based-covid-19-antibody-tests/ - Mologic update on 20th April - MTA with ODX, already in manufacturing, 46000 tests/day production
https://www.lse.co.uk/rns/ODX/covid-19-mta-signed-with-mologic-ltd-chepdhwdztrbaig.html - ODX RNS on 20th April - MTA agreement with Mologic to produce the ELISA lab tests.
https://www.lse.co.uk/rns/ODX/ce-mark-of-covid-19-elisa-antibody-test-i8eaa9hdvc1ezcf.html - ODX RNS on 27th April - ELISA lab test CE mark attained.
Mologic Tweet on 5th May re-confirms ELISA test is already being manufactured as previously notified in Mologic update of 20th April:
“The IgG COVID19 ELISA is the first in a series of diagnostic tests @mologic have developed to support the pandemic response. The ELISA is currently being manufactured with @OmegaDiagnostic and we’re pleased to see its development pathway is now published”.
ELISA test ODX manufacturing news articles:
https://www.ceteris.co.uk/blogs/250-ceteris-work-with-local-companies-in-fight-against-covid-19

MHRA specs:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881162/Target_Product_Profile_antibody_tests_to_help_determine_if_people_have_immunity_to_SARS-CoV-2_Version_2.pdf

2. Rapid Test Consortium – POC (Point of Care i.e. finger prick blood test) testing:
http://www.omegadiagnostics.com/Portals/0/RNS%20MOU%20on%20COVID-19%20Consortium.pdf
- ODX part of RTC to develop and produce POC antibody testing for the masses.
https://www.telegraph.co.uk/news/2020/05/06/coronavirus-covid-antibody-test-home-kit-order/
- Government plans for POC testing
https://vimeo.com/415262977/04659145f9 - REACT2 - antibody ‘home test kit’ video demo used in current REACT2 study
https://online.ipsos-mori.com/media/20-03462601-06/docs/20-034626-01_C-19_ANTIBODY_TEST_HELPLINE_FAQs_v2.2.pdf - antibody ‘home test kit’ FAQ/instrcutions.

Further news articles:
https://www.alloaadvertiser.com/news/18426571.alva-firm-joins-uk-rapid-

Ethio, the Mologic POC test kit has nothing to do with ODX and the Gov backed Rapid Test Consortium. I know it is very confusing but please see my previous posts.

I do not believe the Gov will use the Mologic test for mass antibody testing, for a couple of reasons....
- the Mologic test is only 96% specificity, which does not meet minimum MHRA requirements. The highest specificity is very important as it reduces the chances of a false postive (I have previously mentioned this):
https://mologic.co.uk/preliminary-clinical-performance-data-for-professional-use-covid-19-rapid-diagnostic-test/

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881162/Target_Product_Profile_antibody_tests_to_help_determine_if_people_have_immunity_to_SARS-CoV-2_Version_2.pdf

- both the process that the Mologic POC device uses and the device itself looks nothing like the test being used in the REACT2 study (the Mologic POC test does not use a 'buffer' so the device only has one well, for the blood droplet) :
Mologic device demo here by Sajeev Krishna from St George's hospital is shown here.... https://edition.cnn.com/videos/business/2020/04/17/uk-coronavirus-antibody-test-kit-mologic-nick-paton-walsh-pkg-intl-hnk-vpx.cnn
The REACT2 study device, which I believe to be the antibody POC 'at home' test developed by the Rapid Test Consortium, and being distributed currently to study participants, has two wells, and uses a 'buffer' reagent, is shown here... https://vimeo.com/415262977/04659145f9

and here's the video....
https://vimeo.com/415262977/04659145f9

I think this is it....

https://online.ipsos-mori.com/media/20-03462601-06/docs/20-034626-01_C-19_ANTIBODY_TEST_HELPLINE_FAQs_v2.2.pdf